StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $2.22 | $2.26 | +1.80% | 0.0M |
| 05-12 | $2.25 | $2.28 | +1.33% | 0.1M |
| 05-13 | $2.24 | $2.26 | +0.89% | 0.0M |
| 05-14 | $2.23 | $2.15 | -3.59% | 0.0M |
| 05-15 | $2.14 | $2.03 | -5.14% | 0.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
| Metric | Q1 2022 2022-03-31 | Annual 2021 2021-12-31 | Q3 2021 2021-09-30 | Q2 2021 2021-06-30 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $-2.63M | $-9.26M | $-6.17M | $-4.91M |
Net Income | $-302.00K | $-9.30M | $-6.21M | $-2.31M |
EPS (Diluted) | $-11.62 | $-1.42 | $-0.96 | $-0.79 |
Total Assets | $5.94M | $8.34M | $10.14M | $11.65M |
Total Liabilities | $2.58M | $2.52M | $1.41M | $1.79M |
Cash & Equivalents | $2.54M | $3.70M | $5.88M | $10.46M |
Free Cash Flow OCF − CapEx | Not available | $-8.31M | $-6.73M | $-5.44M |
Shares Outstanding | 6.81M | 6.81M | 6.81M | 4.51M |
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.